徐州无痛胃镜需要多少钱(徐州较好的胃镜医院) (今日更新中)

The US Air Force apologized Thursday for its ill-advised attempt to incorporate the viral "Yanny" or "Laurel" meme into a tweet about repelling a Taliban attack in Afghanistan.In what was clearly a major social media fail, the initial tweet -- which was posted by the Air Force's official account earlier in the day -- attempted to put a playful spin on the popular meme currently sweeping the internet by comparing it to the distinctive sound of the 30mm cannons aboard an A-10 Warthog aircraft."The Taliban Forces in Farah city #Afghanistan would much rather have heard #Yanny or #Laurel than the deafening #BRRRT they got courtesy of our #A10," the tweet said.The tweet has since been deleted and replaced with an apology that said the initial post was "made in poor taste.""We apologize for the earlier tweet regarding the A-10. It was made in poor taste and we are addressing it internally. It has since been removed," the second post said.Politicians, corporate brands and even the Department of Defense's official Twitter account have weighed in on the debate centered around a viral audio clip that says either "Yanny" or "Laurel" depending on the listeners interpretation.But the Air Force's post incorporating the pop-culture reference sparked criticism from those who said it was inappropriate to mention the meme in a tweet about the thwarted Taliban attack .When asked about the controversy on Thursday, Pentagon Spokeswoman Dana White said she wasn't aware of the tweet."What is important to understand is that this is the Afghans' fight. We are working by, with and through these partners. And they are dying to secure their own future and I think that shouldn't be forgotten in any of this," she added.The US military helped Afghan troops repel a major Taliban attack on the Afghan provincial capital Farah on Tuesday and Wednesday that punctured the security perimeter surrounding the city, US and NATO officials told CNN.The Pentagon said Thursday some US advisers assisted in the fight and coalition airstrikes also took place. US A-10 attack jets also flew overhead but did not conduct any strikes.It was unclear how close the Taliban came to capturing the city, which would have represented a major blow to the Afghan government.The insurgents claimed they briefly seized the city center, while the NATO-led coalition said it saw no direct evidence that they ever made it into the city.Afghan A-29 attack planes and Mi-17 helicopters carried out multiple airstrikes in defense of the city.US military advisers eventually arrived in the city to assist Afghan military commanders at their headquarters, helping to call in drone strikes that killed some 28 Taliban fighters, Lt. Col. Martin O'Donnell told CNN.He said US troops also arrived to advise Afghan commando units involved in the counterattack but did not participate in offensive operations. 2877

The United States and Mexico have reached an agreement to change parts of NAFTA, the trade deal that President Donald Trump has derided for years as unfair.Trump announced the agreement from the Oval Office Monday, with Mexican President Enrique Pe?a Nieto dialed in on a conference call.But the deal left open the question of whether Canada, the third country in NAFTA, would agree to the changes -- and Trump himself said he wanted to throw out the name NAFTA altogether."They used to call it NAFTA," Trump said. "We're going to call it the United States-Mexico trade agreement. We're going to get rid of NAFTA because it has a bad connotation."Negotiators for both countries agreed to a new rule that dictates where auto parts are made.Under the current law, about 62 percent of the parts in any car sold in North America must be produced in the region or automakers have to pay import taxes. The new preliminary agreement would require that 75 percent of auto parts be made in the United States and Mexico, according to the U.S. Trade Representative's office.Much of the business world has been worried about Trump's trade policies, and the stock market reacted positively to the news. The Dow rose more than 250 points and the S&P 500 and Nasdaq hit new highs on Monday.The agreement between the two countries could restart negotiations on NAFTA with all three parties -- the United States, Mexico and Canada.Despite Trump's signal that the deal could lead to a bilateral trade agreement between the United States and Mexico, Pe?a Nieto, through a translator, expressed his "desire that now Canada will also be able to be incorporated in this."Mexico and Canada have stood firm on the importance of maintaining the trilateral format of the NAFTA free trade deal, even as Trump has signaled a desire for individual deals with each country."Canada is encouraged by the continued optimism shown by our negotiating partners," said a spokesperson for Canadian Minister of Foreign Affairs Chrystia Freeland."Progress between Mexico and the United States is a necessary requirement for any renewed NAFTA agreement," he said.Negotiations on rewriting the three-country NAFTA agreement began about a year ago.The 24-year-old trade agreement generally prevents the three parties from imposing tariffs on imports from one another. But Trump has called the agreement "the worst deal maybe ever signed" and moved ahead with tariffs earlier this year.In May, the United States imposed steep tariffs on steel and aluminum from much of the world, including Mexico. In response, Mexico slapped tariffs on billion of U.S. goods, including steel, pork, apples, potatoes, bourbon and different types of cheese. Canada imposed tariffs on .5 billion of U.S. goods, including steel, toffee, maple syrup, coffee beans and strawberry jam. 2841

The Wake Forest Institute for Regenerative Medicine says it has a new use for its bioprinting system. In the past they've 3D printed normal-size organs and tissues in hopes of someday implanting them in patients.For the coronavirus, the lab is creating organs using human cells that can be as small as a pinhead. They're focusing on the organs most likely to be infected by the disease. like the lungs.“And so we've been playing with a number of agents to, on both prongs what can make it more infective, what can make it less infective to try to sort this out for the future,” Anthony Atala, director for the institute said.Atala says he hopes the system will help in testing drugs before they hit the market.Drug companies do extensive testing and clinical trials in people before releasing a new medication.Atala says sometimes those companies find no serious side effects, but then years later, discover that it's toxic to patients taking it. Atala says testing a drug using the bioprinting system can tell if a drug is toxic in weeks instead of after years on the market.“Even though we've used the tool extensively for toxicity testing, it's also a tool that can be used for screening,” Atala said. “So we can test agents that are currently being considered for testing against COVID and test the efficacy of the treatment on miniature human organs made up of normal cells”To be clear, Atala said drug tests on 3D printer organs are not meant to replace clinical trials in humans, be are an added step to better predict what will happen in those trials. 1567

The White House on Monday backed down from its threats to revoke Jim Acosta's press pass."Having received a formal reply from your counsel to our letter of November 16, we have made a final determination in this process: your hard pass is restored," the White House said in a new letter to Acosta. "Should you refuse to follow these rules in the future, we will take action in accordance with the rules set forth above. The President is aware of this decision and concurs."The letter detailed several new rules for reporter conduct at presidential press conferences, including "a single question" from each journalist. Follow-ups will only be permitted "at the discretion of the President or other White House officials."The decision reverses a Friday letter by the White House that said Acosta's press pass could be revoked again right after a temporary restraining order granted by a federal judge expires. That letter -- signed by two of the defendants in the suit, press secretary Sarah Sanders and deputy chief of staff for communications Bill Shine -- cited Acosta's conduct at President Trump's November 7 press conference, where he asked multiple follow-up questions and didn't give up the microphone right away."You failed to abide" by "basic, widely understood practices," the letter to Acosta claimed.CNN won the temporary restraining order earlier on Friday, forcing the White House to restore Acosta's press access for 14 days. Judge Timothy J. Kelly ruled on Fifth Amendment grounds, saying Acosta's right to due process had been violated. He did not rule on CNN's argument that the revocation of Acosta's press pass was a violation of his and the network's First Amendment rights.Many journalists have challenged the administration's actions against Acosta, pointing out that aggressive questioning is a tradition that dates back decades.But Trump appeared eager to advance an argument about White House press corps "decorum," no matter how hypocritical.Since the judge criticized the government for not following due process before banning Acosta on November 7, the letter looked like an effort to establish a paper trail that could empower the administration to boot Acosta again at the end of the month.The letter gave Acosta less than 48 hours to contest the "preliminary decision" and said a "final determination" would be made by Monday at 3 p.m.CNN's lawyers had signaled a willingness to settle after prevailing in court on Friday. Ted Boutrous, an attorney representing CNN and Acosta, said they would welcome "a resolution that makes the most sense so everyone can get out of court and get back to their work."But in a new court filing on Monday morning, CNN's lawyers said the defendants "did not respond to this offer to cooperate." Instead, the letter from Shine and Sanders was an "attempt to provide retroactive due process," the filing alleged.So CNN and Acosta asked the judge to set a schedule of deadlines for motions and hearings that would give the network the chance to win a preliminary injunction, a longer form of court-ordered protection to Acosta's press pass.They were seeking a hearing "for the week of November 26, 2018, or as soon thereafter as possible," according to the court filing.A preliminary injunction could be in effect for much longer than the temporary restraining order, thereby protecting Acosta's access to the White House.In a response Monday morning, government lawyers called the CNN motion a "self-styled 'emergency'" and sought to portray the White House's moves as a lawful next step."Far from constituting an 'emergency,' the White House's initiation of a process to consider suspending Mr. Acosta's hard pass is something this Court's Order anticipated," they said.The DOJ lawyers continued to say that the White House had made "no final determination" on Acosta's access, and asked the court to extend its own deadline, set last week, for a status report due at 3 p.m. Monday, in light of the White House's separate self-imposed deadline for the Acosta decision.At lunchtime, Kelly granted the government's request and extended the status report deadline to 6 p.m. Monday.The case was assigned to Judge Kelly when CNN filed suit last Tuesday. Kelly was appointed to the bench by Trump last year, and confirmed with bipartisan support in the Senate. He heard oral arguments on Wednesday and granted CNN's request for a temporary restraining order on Friday."We are disappointed with the district court's decision," the Justice Department said in response at the time. "The President has broad authority to regulate access to the White House, including to ensure fair and orderly White House events and press conferences. We look forward to continuing to defend the White House's lawful actions."Trump seemed to shrug off the loss, telling Fox's Chris Wallace in an interview that "it's not a big deal."He said the White House would "create rules and regulations for conduct" so that the administration can revoke press passes in the future."If he misbehaves," Trump said, apparently referring to Acosta, "we'll throw him out or we'll stop the news conference.""This is a high-risk confrontation for both sides," Mike Allen of Axios wrote in a Monday item about Trump's new targeting of Acosta. "It turns out that press access to the White House is grounded very much in tradition rather than in plain-letter law. So a court fight could result in a precedent that curtails freedom to cover the most powerful official in the world from the literal front row."The-CNN-Wire 5546

The US Food and Drug Administration approved two cancer treatments, Vitrakvi and Xospata, this week after expedited reviews.Vitrakvi, approved Monday, is "a treatment for adult and pediatric patients whose cancers have a specific genetic feature (biomarker)."The FDA said in a statement that it is the second approved cancer treatment that is based on a tumor biomarker instead of the place in the body where the tumor originated.Vitrakvi will be used for the treatment of solid tumors that have an NTRK (neurotrophic receptor tyrosine kinase) gene fusion that do not have a known resistance mutation, that are not metastatic or where surgical removal is likely to lead to severe morbidity, and that have no alternative treatments or have progressed after treatments.NTRK genes are rare but occur in many types of cancer, the FDA said, such as mammary analogue secretory carcinoma and infantile fibrosarcoma.Xospata tablets, approved Wednesday, are for the "treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation," according to the FDA.Alongside the tablets, the agency also approved a diagnostic to detect the mutation."Approximately 25 to 30 percent of patients with AML have a mutation in the FLT3 gene. These mutations are associated with a particularly aggressive form of the disease and a higher risk of relapse," Dr. Richard Pazdur, director of the FDA's Oncology Center of Excellence, said in the statement.AML is a rapidly progressing cancer that affects the numbers of normal blood cells and calls for continuous transfusions, the FDA said.Both treatments were granted Priority Review designation.Priority Review, established in 1992, means the FDA aims to review the drug or treatment within six months, opposed to 10 months for a standard review."A Priority Review designation will direct overall attention and resources to the evaluation of applications for drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications," the FDA says.Both treatments also received?orphan drug?designation, a status granted to drugs for rare diseases or conditions. 2261

来源：资阳报